Phase 3Recruiting
A Randomized, Open-Label, Multicenter Phase III Clinical Study of JS203 Plus Chemotherapy Versus Rituximab Plus Chemotherapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd. (Academic or other)
- Enrolment
- 282 planned
- Conditions
- Diffuse Large B-Cell Lymphoma
- Interventions
- JS203 in combination with gemcitabine and oxaliplatin; Rituximab in combination with gemcitabine and oxaliplatin
- Ages
- adults, older adults
- Registry
- NCT07808827
Full record on ClinicalTrials.gov
From the registry
This study will evaluate the efficacy and safety of glofitamab in combination with gemcitabine plus oxaliplatin (JS203-GemOx) compared with rituximab in combination with gemcitabine plus oxaliplatin (R-GemOx) in patients with R/R DLBCL.
Primary outcomes
- Overall survival (OS)
History
Study completion expected
Primary completion expected
Last registry update
Started
Registered